Cardiovascular disease (CVD) is the leading cause of disease-related death worldwide and
a significant obstacle to improving patients' health and lives. Mitochondria are core …

Anthracycline cardiotoxicity remains a serious problem in paediatric and adult cancer
survivors, and the advancement of cardio-oncology is a necessary step for an effective care …

Engineered tissues can be used to model human pathophysiology and test the efficacy and
safety of drugs. Yet, to model whole-body physiology and systemic diseases, engineered …

Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of
cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases …

Proteasome inhibitors (PIs) are the backbone of combination treatments for patients with
multiple myeloma and AL amyloidosis, while also indicated in Waldenström's …

The interest in non-coding RNAs, which started more than a decade ago, has still not
weakened. A wealth of experimental and clinical studies has suggested the potential of non …

Molecular interactions are key drivers of biological function. Providing interaction resources
to the research community is important since they allow functional interpretation and network …

Clinical therapy of doxorubicin (DOX) is limited due to its cardiotoxicity. miR-146a was
proved as a protective factor in many cardiovascular diseases, but its role in chronic DOX …

In western countries, cardiovascular (CV) disease and cancer are the leading causes of
death in the ageing population. Recent epidemiological data suggest that cancer is more …

Purpose of review As cancer survivor rates improve with early screening and modern
treatment options, cardiotoxicity is becoming an increasing problem. It is imperative for …